Merck

ONTRUZANT

Manufacturer:

Merck

Ontruzant HCPCS:

Q5112

HCPCS Code Descriptor:

Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg

Category:

Q Code

Ontruzant NDCs:

78206-0148-01, 78206-0147-01

Primary Type:

Oncology Biosimilar

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Ontruzant:

ONTRUZANT is an Oncology Biosimilar drug manufactured by Merck and administered via the Intravenous route of administration. The Q Code: Q5112 is aligned to the drug ONTRUZANT.

Ontruzant (trastuzumab) is a cancer drug that targets the HER2 protein in cancer cells. This medication can be used to treat specific types of breast and stomach cancers. Ontruzant can be used in combination with other cancer medications. This drug is manufactured by Merck Sharp & Dohme and Organon and is biosimilar to the medication Herceptin (J9356). Ontruzant has one HCPCS code Q5112, which has been aligned to the medication since July 2019. Patient assistance programs for this medication can be found through the Organon Access Program.

ACCESS PRICING AND MORE BY REGISTERING

Q5112 Added Date:

July 1, 2019

Q5112 Effective Date:

July 1, 2019

Q5112 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Ontruzant billing and coding information.
Ontruzant patient assistance information can be found through The Organon Access Program at the URL: https://www.organonaccessprogram-ontruzant.com/hcc/
ONTRUZANT prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for ONTRUZANT. Please check back in a few weeks.